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Fragile X Syndrome (FxS) is the most common cause of inherited mental 
disability and autism spectrum disorder. Estimated incidence in males is 1 in 4000 and 1 
in 7000 for females. The gene is on the distal end of the long arm of the X chromosome 
and contains a trinucleotide cytosine, guanine, guanine (CGG) microsatellite repeat in 
the 5’ untranslated region (5’UTR) of the gene. When the repeat region is fully 
expanded the CpG island near the gene promoter site becomes methylated, and the 
result is silencing of the gene and loss of protein product.  Health issues that 
correspond to a partially expanded trinucleotide repeat are Fragile X Tremor and Ataxia 
Syndrome (FXTAS) and Primary Ovarian Insufficiency (POI). 
Current molecular detection involves Polymerase Chain Reaction (PCR) 
amplification of the CGG region, followed by capillary electrophoresis (CE) separation 
and fluorescent detection of the PCR amplicon with very high sizing resolution for 
normal and lower range premutation repeats. For larger pre-mutation repeats and full 
mutations, detection is done with digestion of genomic DNA with methylation sensitive 
enzymes, followed by Southern blotting. The Southern blots have some significant 
disadvantages; they are labor intensive, require large amounts of genomic DNA, blot 
sizing of the CCG repeat region has very imprecise resolution, reagents are expensive 
and they have a long processing time.  
Fluorescent detection of PCR product by CE is faster, less expensive, and has 
iv 
much higher resolution, but it has not been useful for the detection of full mutations due 
to PCR inefficiency for large CGG repeats and difficulty of detecting a very large CG 
rich trinucleotide repeat PCR product.  
The purpose of this thesis is an overview of the current molecular paradigms of 
FxS, FXTAS and POI, molecular testing and a comprehensive evaluation of the Celera 
Fragile X assay and the possibility that use of their 1.5% agarose recipe, gel 
electrophoresis (GE) and a long injection capillary electrophoresis protocol can detect 
all premutation and full mutation samples and reduce the need for Southern blotting for 
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 Fragile X Syndrome (FXS) is the most common cause of inherited mental 
disability and autism spectrum disorder.1, 2 In 1991 scientists discovered the 
gene FMR1 (Fragile X Mental Retardation–1) that causes fragile X syndrome. 
The gene is on the distal end of the long arm of the X chromosome and contains 
a trinucleotide cytosine, guanine, guanine (CGG) microsatellite repeat region in 
the 5’ untranslated region (5’UTR) region of the gene. It is evolutionarily 
conserved in many species, with orthologues in other vertebrates and 
drosophila.1 Fragile X Mental Retardation Protein (FMRP) is an RNA binding 
protein and contains common RNA binding motifs: two K-homologous (KH) 
domains and an N-terminus RGG (arginine, glycine, glycine) box (see Figures 1 
and 2).   
 






Figure 2. Fragile X N-Terminal RGG domains ribbon diagram 
http://www.rcsb.org/pdb/home/home.do 
 
 The nuclear localization and export signals on the protein show that FMRP 
is involved in shuttling RNA to and from the nucleus.3  
 The molecular mechanism for the pathology related to FMR1 is expansion 
of the CGG region, with differing sizes of microsatellite repeats corresponding to 
different health and development issues. When the CGG repeat region is fully 
expanded (>200 repeats) the CpG island near the gene promoter site becomes 
methylated and the chromatin shifts from an active euchromatic, transcriptionally 
open confirmation to a heterochromatic, condensed nontranscribing state. 4 This 
methylation extends to the adjacent promoter region and the result is silencing of 
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the gene and loss of protein product. More than 95% of Fragile X Syndrome 
(FxS) incidence is caused by the expansion and resulting methylation of this 
repeat region, and 5% is caused by other gene anomalies, i.e, promoter region 
deletions or nucleotide mutations within the gene.   Fragile X Tremor and Ataxia 
(FXTAS) and Primary Ovarian Insufficiency (POI) are diseases also related to the 
alteration of the CGG region size in this gene, but they have completely distinct 
molecular mechanisms from FxS.5 
The size of the repeat region determines gene functionality and mitotic 
stability of the repeat region. Normal expression of the gene correlates to repeat 
sizes up to 45 CGG repeats. Between 45 and 55 repeats is considered a “grey 
zone” due to the uncertainty and variability of gene expression and the possibility 
of repeat expansion during transmission caused by mitotic instability related to 
haplotype sequence interspersions. The CGG repeat is normally interrupted by 
two stabilizing AGG repeat elements at positions 10 and 20.  Alleles that lack the 
3’ nearest AGG element are more likely to expand upon transmission, and loss of 
both stabilizing AGG elements increases expansion potential even more.  Other 
haplotype markers used in allele expansion association studies are DXS548, 
FRAXAC1 and two dinucleotide markers (CA) 150 and 7Kb distant from the CGG 
repeat. 6   Regions with 55 to 200 trinucleotide repeats are classified as 
premutation (PM) and can be mitotically unstable during oogenesis, depending 
on both the repeat size and the haplotype sequence interspersions. A full 
mutation (FM) of 200-1000 repeats is associated with methylation of the 




FxS is regarded as the most common form of inherited cognitive 
impairment and a prevalence estimate has been reported to be 1 in 4000 for 
males and 1 in 7000 for females, but this is not a consensus. 7 There are 
variations in estimates of its prevalence in the population.  The most common 
estimates are based on population projections from special education needs 
children; this skews the estimates of FxS prevalence. There are likely many 
individuals who exhibit the behavioral, cognitive and learning disabilities 
associated FxS but have border line or near normal IQs, particularly females. 
Additionally, the studies from which these statistics are drawn from are often too 
small to be significant and do not consider possible regional founder effects.  
Paul Hagerman, professor at the Department of Biochemistry and Molecular 
Medicine, University of California, Davis, proposes using prevalence of PM 
alleles in the population from direct screening for large scale populations of 
normal pregnant or preconception women and the known relationship between 
PM alleles and the statistical frequency of expansion to FM allele. Using this 
method of prevalence estimate, there would be 1/2,500 FM in the population for 









A fully expanded CGG repeat (>200 repeats) is associated with a 
complete loss of protein product. Affected males are always symptomatic with 
possible variable expression due to repeat size mosaicism and have 
developmental issues that present in early life and persist with a life-long 
behavioral phenotype. Patients affected with FxS exhibit intellectual disabilities 
with IQ’s ranging from 20 to 70, speech and language impairment and autistic 
like behaviors, including anxiety, irritability, unstable moods and deficits in pre-
pulse inhibition to stimuli, usually acoustic.2, 8 In addition, 20% of affected 
patients experience seizures of either benign epileptic or audiogenic types.9-11 
The cognitive dysfunctions include deficiencies in working and short term 
memory, executive functions, mathematic and visual-spatial abilities.12 The 
neuronal dendritic spines in the brains of FxS patients are immature, elongated 
and thin due to incomplete synaptogenesis.13  Cognitive impairment appears 
initially mild in males but seems to become more severe with age. Females can 
have a less severe phenotype, due to the protective effect of random X 
chromosome inactivation.14 The majority of full mutation females are affected 
cognitively with 70% demonstrating an IQ in the borderline or mentally retarded 
range. The remaining 30% of females have IQs in the normal range, but can 
have learning disabilities and emotional problems.15 
Behavioral aspects vary with age and gender and can include autistic-like 
behaviors including poor eye contact, perseverative speech, tactile 
defensiveness, shyness, social anxiety, hand flapping and biting.  Anxiety and 
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mood disorders, hyperactivity, impulsivity and aggressive behaviors are often 
present with varying severity.13, 16 
  In addition to incomplete neural development, cognitive impairment and 
behavioral hallmarks, there are several physical features associated with the FxS 
phenotype including craniofacial anomalies, i.e., a long face, a large prominent 
jaw, elongated or everted ears and close interocular distance. 1, 17 Patients may 
also exhibit flat feet, hyperextensible finger joints, hand calluses, strabismus and 
machroorchidism in males and enlarged ovaries in females. The representation 
of the physical hallmarks is similar in both males and females before puberty, 
with the proportion of females with physical hallmarks being slightly less in some 
features.  Postpubertal females show the physical hallmarks about half as 
frequently as postpubertal males. 15  
 
FxS Molecular Basis 
The syndrome name comes from the appearance of a chromosomal 
fragile site when cells with an expanded CGG region are cultured in a medium 
deficient in folic acid.1 The FMR1 gene codes for FMRP, an mRNA binding 
protein that appears to be a key player in neuronal synaptic plasticity through 
negative translational control and transport of mRNAs as a molecular 
chaperone.18  When the repeat region is ≥200, the initial pathogenic event is the 
methylation of the CpG region in the 5’(UTR). Early germ cells from full-mutation 
fetuses have expanded repeats but are unmethylated, whereas cells taken from 
chorionic villi samplings from full-mutation fetus’s show FMR1 hypermethylation 
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that increases in proportion to the degree of development. This demonstrates 
that the gene silencing happens during embryonic development and is a dynamic 
process. 4, 19, 20 The mechanism of this event is unknown but is widely recognized 
as the cause of gene silencing because of the existence of rare patients with full 
mutation repeat regions but no CpG methylation that do not exhibit the FxS 
phenotype and are not gene mosaics.21, 22  This epigenetic change alters the 
structure of the gene. The methylated CpG residues are recognized by methyl 
binding proteins, and a multiprotein complex is recruited with histone 
deacetylases (HDACs) resulting in condensation of chromatin. This restricts 
access of polymerase and transcription factors to the promoter region preventing 
transcription. 23 
The loss of FMRP in dendrites and synaptic junctions has multiple 
downstream effects due to the fact that the protein is a chaperone of many 
mRNA’s that are involved in synaptic functioning.  The candidate downstream 
targets identified in this cascade include a significant percentage (>4%) of brain 
mRNAs, particularly those containing a G-quartet structure or a uracil rich 
sequence. 13  
The FMRP targets are involved in multiple critical neuronal systems, 
including cytoskeleton modeling, mRNA translation repression, and signal 
transduction. The loss of the protein impacts neuronal plasticity during 
development, preventing neuronal maturation and synaptic function.8, 9  FMRP is 
cytoplasmic but has nuclear localization and nuclear export signals involved in 
shuttling the bound mRNAs into the nucleus. The nuclear proteins targeted are 
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involved in mRNA translation and/or dendritic transport inducing local protein 
synthesis in the vicinity of activated synaptic spines.24  
Neurotransmitters (NTs), mostly glutamate, and neurotrophic factors such 
as brain derived neurotrophic factor (BDNF) activate synthesis of FMRP at 
synaptic junctions in normal patients. 20 The glutamate targets the mGluR5 
metabotropic receptor and induces local synthesis of FMRP at the synapse. The 
presence of FMRP is an inhibitor of mGluR5 stimulation by negative feedback. 
Loss of the FMRP feedback regulation results in an increase in mGluR activation 
and a loss of inhibitory signaling in the neurons. FMRP is a negative regulator of 
transcription so in the neurons in FXS patients the absence of FMRP leads to an 
increase of the internalization of these ionotropic and metabotrophic glutamate 
receptors which results in excessive neuronal long term depression (LTD; long 
lasting decrease in synaptic connectivity) and weakening of synaptic 
connections.25  LTD and LTP (long term potentiation) are known to be involved in 
learning and memory; this relates to the cognitive disabilities in FxS patients.  
The mGluR model is supported by a study where mice that are Fmr1(-
/Y)Grm5(+/-) show substantial correction of deficits in neural plasticity and 
normalization of dendritic spine density.13 The mechanisms behind the hyper-
excitability leading to seizures are also linked to the mGluR model. 
Epileptogenesis is related to the failure to modulate the mGluR5 response in the 
absence of FMRP results in neuronal hyperexcitability. The generation of 
neuronal current reduces excitatory input to inhibitory neurons and overall 
increase in neuronal circuit excitability.26  
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Other perturbations in cellular signaling extend to gamma-amino-butyric 
acid (GABA) gated anion channels and to other non-mGluR G-protein-coupled 
receptors (GPCRs), including dopamine receptors and acetylcholine receptors.27 
GABAergic signaling is the major inhibitory neurotransmitter in the central 
nervous system (CNS). It is likely that FMRP related dysregulation of this system 
also contributes to increased neuronal excitatory behavior and seizures.26 
FMRP plays an important role in expression of the structural proteins, 
microtubule-associated protein (MAP1B) and neuron-enriched acidic protein 
having a molecular mass of 22 kDa (NAP22) in the dendrites after specific 
triggering. Loss of FMRP causes abnormal synaptic protein synthesis that 
underlies the variable symptoms of FxS including the presence of immature 
spines and impaired synaptic maturation. In association with polyribosomes and 
microtubules, FMRP helps regulate the formation and pruning of dendrites.13, 28 
 
Treatment FxS 
Treatment for FxS patients is currently supportive and behaviorally 
targeted to maximize functioning because there are no FDA approved 
pharmacological strategies directed at the specific neuronal defect of FMRP 
absence. Symptom based treatment of the most problematic behaviors can be 
helpful. Standard treatment includes special education, speech, occupational, 
and sensory integration training and behavior modification programs. Surgical 
correction of heart defects is sometimes necessary.29, 30 Table 1 describes the 
symptomatic medications that are current standard of care.   
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Sleep Disturbances Trazodone 
Melatonin 
 
There is research currently in progress to identify pharmacological targets 
in the syndrome. The most interest is in the mGluR5 post synaptic glutamate 
receptor and the gamma-aminobutyric acid-ergic (GABABergic) system. In a 
Fmr1 knock out mouse, progress has been made towards rescue of behavioral 
and structural abnormalities with the mGluR5 post synaptic glutamate receptor 
antagonist fenobam, which reduces mGluR5 activation of downstream 
processes, as does Lithium.17 A pilot, open label, single dose trial of fenobam 
showed the positive effects seen in animal models of FXS was replicated in 9 of 
12 human subjects who had IQs ranging from 36-85. Improvements included 
improved prepulse inhibition, calmed behavior, increased eye contact, cognition 
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and interaction.11, 13 Arbaclofen, a prodrug for the GABAB receptor agonist, 
Baclofen, has been shown to decrease the irritability and aberrant behavior seen 
in FxS and is also undergoing clinical trials. Aripiprazole is an antipsychotic that 
is being evaluated for FxS patients as well and could be effective in decreasing 
aggression, self-injurious behavior, agitation, and repetitive behavior commonly 
observed in individuals with FxS.10, 15 FMRP replacement therapy is being 
studied in Fmr1 knock out mouse models of FxS. Scientists at University of 
Florida College of Medicine have constructed an adeno-associated virus vector 
that expresses the central nervous system isoform of FMRP. The fmr1 knock out 
(KO) mouse phenotype showed rescue from the long term depression that may 
be linked to cognitive impairments associated with FxS. Analysis of hippocampal 
synaptic function in these mice showed that the paired pulse low frequency 
stimulation induced LTD was restored to WT levels.31 
 
FXTAS  Prevalence 
One in 813 males and one in 259 females of the general population carry 
a PM allele. Different ethnicities show different prevalence, the PM allele is less 
common in Asian populations, more common in Mediterranean groups. A recent 
study of 40,000 women in Israel showed 1/154 with the PM allele.21 Penetrence 
and incidence of FXTAS, including age of onset and severity of symptoms, is 







Premutation carriers with a CGG repeat region between 55 and 200 in 
FMR1 do not show fragile X syndrome phenotypes but can experience other 
serious health issues, usually late onset syndromes around 40 or 50 years of age 
or later. 9, 33, 34  The most common late onset disorder is Fragile X Tremor and 
Ataxia Syndrome (FXTAS). The syndrome was not described until about 10 
years after the discovery of FMR1 in 1991. Geneticists were focused on the 
developmental disorder associated with mental retardation. Pediatric clinics had 
little contact with aging relatives of patients with FxS so the age associated 
symptoms were not recognized as being related to carrier status. 35 
 Clinical features of FXTAS include Parkinsonian like intention tremor, gait 
ataxia, peripheral neuropathy, cognitive decline beginning with memory deficits, 
psychiatric problems and autonomic dysfunction (high blood pressure, 
impotence, bladder/bowel control). FXTAS is observed in 40% of male carriers 
older than 50 years of age. It is also observed in females, although at a lower 
rate of incidence, again due to the protective effect of random X inactivation.14 
The penetrance of the phenotype increases with age and number of CGG 
repeats.35-37   This makes FXTAS one the most common causes of tremor, ataxia 
and cognitive decline among older adults. 38 
Other clinical features include brain atrophy with white matter disease and 
characteristic hyperintensity in the middle cerebellar peduncles. The psychiatric 
problems, including schizoid, obsessive-compulsive, phobic and psychotic 
symptoms are likely due to neurodegeneration in the amygdala, as memory 
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deficits are due to the same in the hippocampal regions.5, 39, 40   
The behavioral problems seen in FXTAS include significant deficits in 
ability to inhibit prepotent impulsive responses and impaired selective attention. 
In one study of PM males the inhibition deficits developed at age 30 onwards and 
severity of this behavior was seen as a neurological sign preceding cognitive 
deficits, tremor and ataxia to develop later in the PM male carriers’ life.17, 39, 41 It is 
generally accepted that premutation carriers have normal IQ until late onset of 
cognitive decline.40, 42     
 
FXTAS Molecular Basis 
Premutation carriers have 5-10 times the abundance of FMR1 mRNA due 
to a hyperactivated promoter region and possible negative feedback 
mechanisms, but slightly reduced abundance of the functional protein relative to 
normal patients.43 The resulting RNA toxicity from mRNA over abundance is the 
accepted cause of FXTAS and several other trinucleotide repeat (TNR) diseases, 
but the exact mechanism for the RNA neurotoxicity is debated and there are 
many studies of the various downstream affects. The resulting dysregulation from 
the toxic gain of function mRNA affects a number of proteins as well. 
 In both mouse and drosophila models the FXTAS phenotype is observed 
when an expanded CGG repeat is transcribed upstream of an unrelated reporter 
gene.35, 44, 45 The presence of RNA CGG repeats outside the context of Fmr1 is 
sufficient to produce ubiquitin positive inclusions. This supports a theory that 
expanded CGG repeat regions form a short artificial hairpin structure that 
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resembles a heteroduplex. This structure can bind to and sequester RNA binding 
proteins. Additionally, ribonuclease Dicer cleaves long C(any nucleotide)G repeat 
regions into structures that resemble regular duplexes despite many basepair 
mismatches. 46 These duplexes may trigger cellular responses, like the RNA 
interference (RNAi) or micro RNA (miRNA) pathways, that down regulate 
transcription.45, 47 
A different theory states that rCGG binds with and sequesters the proteins 
hnRNP and CUGBP1, that are involved in transcription, mRNA trafficking, 
splicing and translation. This theory is supported by experiments where over 
expression of these two proteins suppress Fragile X CGG PM repeat-induced 
neurodegeneration in a drosphilia model.35, 48  
Another theory is that the excess rCGG repeat binds many other mRNA 
binding proteins that are involved in regulation of mRNAs involved in RNA 
splicing. The neuropathology of FXTAS includes the presence of ubiquitin and 
FMR1 mRNA positive nuclear inclusions in the neurons of affected patients. The 
presence of about 30 proteins has been observed by mass spectrometric 
analysis of neuronal inclusions. The size of the premutation repeat is directly 
proportional to the severity of the FXTAS symptoms, earlier age of onset and the 
proportion of inclusion bearing hippocampal and cortical neurons. 5, 35, 37, 47 
The protein FMRP is expressed in many tissues, but more highly in 
gonads and brain.15 This organ specific expression might account for both the 
late onset premutation health issues linked to FXTAS neurological and POI 
phenotypes by mRNA toxicity and also the cognitive developmental issues in 
15 
 
FXS from gene silencing and lack of protein expression .1, 35 
 
FXTAS Treatment 
Currently, there are no targeted therapeutic interventions that affect the 
pathogenesis of FXTAS. The treatment approaches are symptom based and 
there are neuroprotective agents that may slow the course of FXTAS. The drugs 
used for treatment of the tremor are primidone, beta-blockers, benzodiazapines 
and memantine. Propranolol, a B-adrenergic blocker is the most effective 
treatment of tremor. Botulinium toxin injections have had some success with 
tremor as well. Deep brain magnetic stimulation has been reported on 3 patients 
with tremor with a marked reduction in tremor for about 4 months although gait 
ataxia persisted.  Ataxia has shown improvement in patients treated with 
cabidopa/levidopa, dopamine agonists and eldepryl. Physical therapy can be 
useful for improving strength and gait. The treatment of related cognitive defects 
and dementia is based on off-label application of dementia treatments 
conventionally used in Alzheimer’s disease (AD). Cholinesterase inhibitors are 
used for memory impairment. Psychiatric problems that occur prior to the onset 
of FXTAS can be treated with antidepressants and antipsychotics along with 
cognition enhancers.  Autonomic dysfunction, such as urinary urgency and 
frequency has been treated with injections of botox into the lining of the 
bladder.32 
Diet and exercise have been evaluated as treatment targets in Alzheimers 
Disease, dementia and related conditions. The nutritional deficiencies that impact 
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patients with FXTAS should be similar to other cognitive and movement related 
disorders. Deficiencies in B vitamins like folate and B12 are common in elderly 
patients and are associated with increased risk of cognitive decline and 
dementia. Hyperhomocysteinemia occurs with low folate or vitamin B12 and is 
associated with increased prevalence and incidence of AD and dementia.  Both 
vitamins are involved in the synthesis of S-adenosylmethionine (SAM) which is a 
methyl donor for a variety of methylation reactions, including those involving 
neurotransmitters, membrane phospholipids, myelin and DNA.  The B vitamin 
has been associated with depression which is also a symptom in FXTAS.32 
 
POI Prevalence 
Of the 1/259 female carriers of the PM allele and 20% have Primary 
Ovarian Insufficiency (POI), defined as amenorrhea or cessation of menstruation 
at or before 40 years of age, compared to 1 % in the normal population.21, 35  An 
additional 20% of PM carriers show POI before the age of 45. 1, 35 There is a 
study that reports that POI preferentially affects women who inherited the 
premutation from their fathers, suggesting an imprinting phenomenon, but other 
studies failed to confirm these findings.49 Full mutation carriers do not have POI; 
they have the same risk of ovarian dysfunction as noncarrier women.1, 49, 50  
Studies correlated the size of the premutation repeat region with ovarian 
dysfunction and a positive, nonlinear association with CGG repeat number and 
age at POI onset was found. Women with POI were more likely to have a midsize 
repeat region around 70. Women with PM regions over 100 were less likely to 
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POI is the development of amenorrhea, with sex hormone deficiency and 
elevated serum gonadotropin levels before age 40. The ovaries stop functioning 
normally, sometimes with the permanent cessation of menses.49   One group 
found that there was no difference in the occurrence of diseases known to be 
associated with menopause, such as cardiovascular diseases and osteoporosis 
in premutation patients with POI relative to normal patients. Premutation status 
may affect the ovaries, but does not substantially increase the risk for additional 
medical problems.50 The fact that patients with full mutation alleles do not have 
POI supports that this phenotype is not related to fact that they have an average 
of 50% of cells that are devoid of FMRP.  Women with the PM that are still 
cycling have higher levels of follicle stimulation hormone (FSH) than healthy 
women as well as elevated gonadotropin levels.1, 19  
 
POI Molecular Basis 
There are no reports for the mechanism of POI, although studies have 
shown that it is related to the toxic mRNA gain of function effect. Further 
investigations are needed to understand the molecular pathways underlying POF 





Management of POI is directed at symptom resolution. Hormone 
replacement therapy with oestradiol and progesterone is necessary to protect 
bone mass. Fertility treatments are not shown to increase pregnancy rates for 
patients with POI so psychosocial counseling and alternate family planning are 
recommended to accompany the diagnosis.51  
 
FMR1 Inheritance 
 Inheritance of Fragile X syndrome and the premutation associated 
disorders differs from other X linked diseases, due to the mitotic instability and 
possible expansion of the PM repeat region. Carrier men pass a premutation 
unchanged and stable to all of their daughters but none of their sons. Normal and 
grey zone alleles are more unstable when transmitted through males.25, 52   Each 
child of a carrier woman has a 50% chance of inheriting the PM allele. It can be 
transferred in a stable and unexpanded form or, due to the instability of the 
premutation region during oogenesis, the allele can expand into a higher 
premutation or the full mutation range, and Fragile X syndrome. The Fragile X 
premutation can be passed silently down through generations in a family before 
novel expansion of the gene occurs and the syndrome affects a child. The larger 
a repeat region, the more likely it is to expand to a full mutation during meiosis, 
adding increasing genetic anticipation to the inheritance incidence.  Expansion 
risk is also related to the presence of the two AGG triplets within the CGG region 
(usually at positions 10 and 20) that have a stabilizing effect during mitotic 
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replication. Loss of one or both of the AGG triplets increases expansion risk.53-56 
The smallest repeat to expand to full mutation in one generation was 59 repeats 
and had loss of both stabilizing AGG segments.55 In the same study, for 664 
pregnant women with partially expanded FMR1 genes, the overall risk of full 
mutation among PM mothers that transmitted the PM allele is summarized in 
Table 2. The study showed no differences in repeat expansion with respect to 
gender of fetus.55 
The proposed mechanism of expansion involves slippage at the 
replication fork. Unpaired bases form loops, which result in expansions or 
contractions depending on whether the loop is on the template strand or on the 
synthesis strand. Large expansions likely involve displacement synthesis of 
Okazaki fragments. The hairpin structures formed include Watson-Crick base 
pairing that tolerates many mismatches. The unusual secondary structures of 
these hairpins may stall polymerases, resulting in large expansions. Unlike some 
other TNR diseases like DM1, there is no repeat instability in somatic cells.19, 20 
 
Table 2. Transmission percentage of FMR1 PM alleles as FM alleles.55  










Because of the multigenerational expression and variable phenotypes of 
fragile X-associated neuropsychiatric illness, there is a prominent role for genetic 
testing and genetic counseling of patients and their relatives. Genetic testing can 
be confirmatory for both full mutation and premutation of the FMR1 gene and is 
an essential component of the clinical evaluation for families of FxS patients. 
Gray zone results (between 45-54 CGG repeats) should be interpreted within the 
context of the family and clinical history because of the uncertainty of expansion 
risk and expression variability.11 
 Current molecular detection involves Polymerase Chain Reaction (PCR) 
amplification of the CGG region, followed by capillary electrophoresis (CE) 
separation and fluorescent detection of the PCR amplicon with very high 
resolution for normal and lower range premutation repeats. For larger 
premutation repeats and full mutations, detection is done with digestion of 
genomic DNA with methylation sensitive enzymes, followed by Southern blotting 
(SB). The Southern blots have some significant disadvantages; they are labor 
intensive, require large amounts of genomic DNA, reagents, long processing 
time, and expensive reagents, and blot sizing of the CCG repeat region has very 





Figure 3. Southern Blot of 10 Patients. (www.currentprotocols.com/protocol/hg0905 
accessed 12/13/2009) 
 
Fluorescent detection of PCR product by CE is faster, less expensive, and 
has much higher resolution, but has not been useful for the detection of full 
mutations or large premutation alleles due to PCR inefficiency for large CGG 
repeats, preferential amplification of normal alleles and the difficulty getting large 
PCR fragments through the capillary. Apparent homozygous females and 
mosaics with PM/FM or normal/FM genotypes are not detected by CE so the SB 





Full Mutation Male. 
Methylated Repeat→ 
Full Mutation Female 














  The Celera and Abbott Molecular fragile X research assay is a PCR assay 
that co-amplifies a gender-specific marker simultaneously with FMR1 CGG triplet 
repeats up to 645 repeats, and sizes repeats up to 230 by fluorescent capillary 
electrophoresis (CE) on ABI ® 3130 Genetic Analyzer. 
By using the Celera and Abbott Molecular Fragile X detection kit with CE 
and 1.5% Seakem and Nusieve agarose gels with UV detection, full mutation and 
premutations will be detected without Southern blotting. This study will determine 
whether or not Southern blotting can be eliminated from the Fragile-X detection 
protocol for the following genotypes: normal, premutation and full mutation 
females and males as well as mosaics.  The Southern blot could be performed 
as a reflex on full mutation samples for confirmation of full mutation expansion 
and methylation status. 
This study will attempt to answer the following questions; 
• Will a combination of gel electrophoresis (GE) and CE be useful for 
detecting male full mutations, female full mutations and mosaics? 
• Will a longer injection protocol on the 3130xl Analyzer improve 
detection of full mutations? 
• Will the combination of the Celera gel detection and CE enable 













Two hundred and fifty-nine premutation, full mutation and mosaic males 
and females from archived patient DNA were used for this study and amplified 
with the Celera and Abbot Molecular Fragile X kit. The DNA samples have been 
previously detected by PCR with either  A.R.U.P.’s laboratory developed PCR 
assay with ABI 377 polyacrylamide slab gel fluorescent electrophoresis used 
from 2003-2006 or the Celera and Abbott Molecular kit and capillary 
electrophoresis using lab developed injection parameters. All samples were 
deidentified so it was not possible to distinguish which samples were detected 
with which methodology.  All samples had been previously detected by Southern 
blot.  Sample genotypes include CGG repeat regions from females and males 
with sizes in the grey zone (45-55), premutation zone (55-200), full mutations 
(200-1000) and genotype mosaics. The genotypes of the five mosaic patients 
were; female with three normal alleles, female with a full mutation, a premutation 
and a normal allele, male with two normal alleles, male with both  premutation 







 Perkin Elmer 9700 thermocyclers were used for DNA target amplification 
by polymerase chain reaction with the Celera Abbot Molecular kit. The products 
were detected by fluorescent CE on the ABI 3130 genetic analyzer with both 
standard and long injections and run on Celera design lab made 1.5% Nusieve 
and Seakem agarose gels.  
 
DNA Extraction 
DNA was obtained from whole blood samples using the MagNA Pure ® 
System by Roche Diagnostics. It incorporates the use of magnetic silica beads, 
which allows DNA to bind to a silica surface to be transferred via magnetic 
charge. A total of 32 samples are processed in approximately 1 hour using the 
DNA I Fast Protocol. The process initially involves transferring samples into a 32-
well sample cartridge. The cartridge is placed on the MagNA Pure along with all 
of the required reagents and disposable plastics. First, the MagNA Pure 
dispenses reagents into the respective areas in the processing blocks; lysis 
buffer is then added directly to the sample and mixed 1 row at a time. Next, the 
lysate is transferred to the processing block where it is dispensed into a row of 
wells filled with Proteinase K. Following room temperature incubation the 
samples are transferred to the next set of wells containing the magnetic silica 
beads. The DNA attaches to the beads and is then transferred via a magnet to 
wells containing wash buffer. The beads are subsequently washed and 
transferred (via magnet) to a sample cartridge that is preheated, allowing the 
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DNA to dissociate from the beads. The magnetic beads are disposed into the 
waste area and the elution buffer is transferred into the final sample cartridge, 
cooled at 4º C. One more disposal of beads occurs to eliminate any residue. 
Samples are then eluted for PCR amplification. 
 
PCR Amplification 
Extracted DNA was amplified by PCR using Celera and Abbott Molecular 
Fragile X ASR reagents. The master mix was prepared in a dedicated PCR area, 
free of amplicon. Table 3 indicates the volume of each reagent required for 
formulating the working master mix for a single PCR reaction and cycling 
conditions are described in Table 4.  
 
Table 3. Reagent volumes for PCR amplification mix 
Reagent Name Volume for 1 PCR Reaction (uL) 
High GC PCR Buffer 13 
Gender Primers 0.6 
Fragile X Primers 0.8 
TR PCR Enzyme Mix 1.2 







Table 4. PE 9700 thermal cycling conditions for PCR reaction.  
Temperature(°C) Time (min:sec) Cycles Volume (uL) 







98.5AutoX+0.1°C/cycle 0:10 15 
56.0 1:00 
75.0 6:00 
4.0 ∞ - 
 
 
The master mix was vortexed and aliquoted into a 96-well plate. Three uL of 
extracted DNA was added to each well. The plate was centrifuged for 10 
seconds at 500-2000x g to position the solution to the bottom of the tubes. The 
reaction was placed into a Perkin-Elmer PE 9700 thermocycler with the thermal 
profile in Table 4 and maximum ramp speed.  
 
PCR Cleanup 
Following PCR amplification, the product was put through a PCR product 
cleanup step in a postamplification area to remove unincorporated primers and 
dNTPs. In a new 96 well plate 3uL of CleanUp Enzyme  provided by Abbott 
Molecular was added. Two uL of PCR product was added. The plate was 
centrifuged for 10 seconds at 500-2000 x g. The plate was placed in the thermal 
cycler with the Clean Up Program in Table 5.  
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Table 5. PCR cleanup PE 9700 thermal conditions. 
Temperature Time Volume 





After the cleanup cycle the samples were prepared for capillary 
electrophoresis on the ABI 3130 Genetic Analyzer. The electrophoresis mix was 
prepared in a microcentrifuge tube as described in Table 6, for a total of n+2 
reactions. The ingredients were vortexed prior to use. The electrophoresis mix 
was aliquoted to the 96-well electrophoresis plate and 5uL of cleaned PCR 
product was added. The plate was briefly centrifuged and then placed into the 
thermocycler for the denaturation program in Table 7.  
 
Table 6. Electrophoresis reaction mix reagent names and volumes. 
Reagent Name Volume for 1 Reaction 
Hi-Di  Formamide 17.0 uL 
ROX  1000 Size Standard 3.0 uL 





Table 7. Denaturation thermal conditions. 
Temperature Time Volume 
93°C 30 sec  
25uL 25°C ∞ 
 
The samples were placed on the 3130 analyzer and injected with both a 
short injection protocol and a long injection protocol. The parameters of the 
injection modules are listed in Table 8. Fluorescent signal from the PCR product 
is detected by a CCD (charge coupled device) camera on the 3130xl analyzer, 
and the base-pair size determined by comparing the signal with the internal 
Genescan ROX 1000 bp size standard ladder by Genemapper ® analysis 
software.  
 
 UV Agarose Detection 
The agarose gels used were made with the following protocol. As listed in 
Table 9, a 1.5 % gel mix was prepared in a 500mL flask. The agarose mix was 
heated in a microwave oven to dissolve agarose, then 10uL of 10mg/mL ethidium 
bromide was added and mixed by swirling the flask. The mixture was cooled in a 
water bath until slightly viscous. The solution was poured into a gel cast box and 
left to set for 1 hour at room temperature. Samples were prepared for gel loading 





Table 8. Injection protocol parameters 




Oven Temperature 60°C 60°C 
Poly_fill_Volume 6500 6500 
Current Stability 5.0 uAmps 5.0 uAmps 
Pre Run Voltage 15.0 kV 15.0 kV 
Pre Run Time 180 sec 180 sec 
Injection Voltage 2.0  kV 10.0  kV 
Injection Time 2 sec 22 sec 
Voltage Number of Steps 30 nK 30 nk 
Voltage Step Interval 15 sec 15 
Data Delay Time 120 Sec 120 Sec 
Run Voltage 8.5 KV 8.5 KV 
Run Time 2700 Sec 4000 Sec 
 
.   
Table 9. 1.5% agarose gel mixture volumes and components. 
Components Amount 
Molecular Grade Biology Water 180mL 
NuSieve GTG Agarose 2g 
SeaKem GTG Agarose 1g 
10X Tris Borate EDTA(TBE) Buffer 20 mL 
Total Volume 200 mL 
30 
 
Table 10. Agarose gel loading preparation. 
Components Volume 
PCR Product 10uL 
6X Loading Dye Solution 2 uL 
Total 12 uL 
 
 
The preparation for the gel size standard was prepared as described in Table 11. 
It contained DNA GeneRuler bp Ladder Plus (see Figure 4). 
 
Limitations 
Many of the archived DNA samples were degraded as shown by PCR 
failure of the gender control marker and subsequent analysis of a UV smear 
signal consistent with degraded genomic DNA with agarose UV detection. 
Sample replicates for all samples were not possible, as sample DNA volumes 
were limited. The gels were very soft, fragile and difficult to load product on. 
Many of the poor UV signals were due to gel tears and reloading was not an 
option. The low agarose fluorescent signals required 10uL of PCR product per 
load.  PCR product volume was 20uL and 2uL minimum volume was needed for 
CE. The 3130xl also has a high incidence of failed injections, so additional PCR 




Table 11. DNA GeneRuler bp Ladder preparation for agarose gel. 
Components Volume 
DNA Ladder 1.0 uL 
6X Loading Dye Solution 7.0uL 
Molecular Grade Biology Water 4.0 uL 



















Of 259 samples 22 would not amplify for gender marker control or tri-
nucleotide alleles. This is likely due to DNA degradation from extended frozen 
storage of samples. Samples that had amplification of the gender marker, but no 
amplification for the CGG repeat were not considered degraded. These samples 
were repeated and the gels checked for smear characteristic of degraded 
genomic DNA. One sample had no DNA volume in the sample tube.  No results 
were obtainable for these samples. 
Fourteen samples showed genotypes of gender and/or allele size that did 
not match their labels. Due to the many stages of labeling in the storage and de-
identification process, it is likely these samples were mislabeled. Samples were 
repeated to confirm. Since the labels obviously didn’t match the genotypes (i.e., 
gender mismatch, alleles clearly not matching the label) these samples are not 
included in the results. The labeled and actual genotypes are listed in Table 12. 
Table 13 shows the breakdown of samples that had results, or were mislabeled, 






Table 12.  Mislabeled samples with label genotype and detected genotype.  




16 M400 F30 
57 M530 M27 
73 M45 F45/30 
78 F600/26 F72/26 
85 F500/30 F57/29 
98 M67 F66/30 
107 M260/30 M no 
detection 
108 F45 F44/30 
124 M47 F25 
125 F210 M46 
127 F750 F74 
154 F209/45 F29/45 
171 F102 F98/30 
236 F260 F30 
 
  
Table 13. Samples that were tested, mislabeled, degraded or absent. 
Total samples tested 259 
Total samples mislabeled 14 
Total samples with DNA Degradation  22 
Samples with no DNA  1 





Long Injection Protocol 
The DNA samples were from archived DNA, some of the samples are 
several years old. This resulted in some samples not being amplified at all and 
others having some amplification, but very low signal. All of the samples were 
injected with a short injection protocol and a long protocol in order to ascertain 
whether this would enable detection of full mutations or large premutations. The 
long injection protocol was not useful for detection of large repeats, but some of 
the samples with very low amplitude on the short injection protocol resolved with 
better amplitude with the long injection protocol. Out of 16 samples with very low 
amplitude (<100) on the allele of interest, 4 resolved with ≥40% greater peak 
amplitude.  Figure 5 shows example electropherograms (EP) of a sample that 
resolved with better amplitude.  
 
 




The FX alleles increase from 75 fluorescent units to 176 for the 29 repeat 
allele and an increase from 27 fluorescent units to 46 for the 50 repeat allele. 
Samples with a robust PCR amplification and detection actually showed a 
drastic loss of peak amplitude with the long injection and a noisy peak. This could 
be due to irregular current patterns caused by too much product in the injection 
mixture in the system impeding the capillary flow. High salt concentration in the 
injection mixture disturbs the electrokinetic injection. Figure 6 shows EP where 
the peak amplitude decreased with the long injection protocol. 
 
 
Figure 6. Loss of peak amplitude for long injection. The peak amplitude drops 
from 4869 fluorescent units to 514 for the FX allele and the peak is distorted on 




Evaluation of Capillary Artifact 
Of all the full mutation samples with good amplification for gender marker 
control, 17/23 females and 38/43 males had a fluorescent artifact within the 825 
bps region or 205-211 repeats. This artifact is seen on most of the short 
injections and none of the long injections. The high number of full mutation 
samples with good amplification that had the artifact would suggest that the 
presence of this artifact implies full mutation product is present and is giving 
signal at this range of basepairs. This artifact was not seen on any of the 
samples where CE showed no product and was present in one premutation 
male. It was smaller in amplitude in female full mutations with a normal allele, 
which is to be expected with the shorter, normal alleles preferentially amplifying. 
Figure 7 shows examples of the artifacts appearance on 3 out of the 56 full 
mutation patient electropherograms.  
 
Assay Sensitivity and Specificity 
The genotypes and the number detected for male FM and PM, female FM 
and PM, and mosaics are listed in Table 14. The sensitivity of the assay for each 
genotype is listed in Table 15 for all the genotypes tested and includes samples 
that resolved with the long injection protocol. The specificity for all the genotypes 
tested by all three methodologies-CE alone, CE with the 211 artifact and with CE, 













Table 14. Patient sample genotype detected by CE, CE + 211, CE+211+ UV 





CE + 211 
artifact 
Detected by CE 
+ 211 artifact + 
UV gel 
Male FM 43 0 38 39 
Female FM 23 0 17 17 
Male PM 65 65 65 65 
Female PM 86 85 86 86 
Mosaic Female 3 
Normal alleles 
1 1 1 1 
Mosaic Female 2 
Normal and 1 FM 
allele 
1 0 1 1 
Mosaic Male 2 
Normal alleles 
1 1 1 1 
Mosaic Male 2 
different size FM 
alleles 




Table 15. Sensitivity (True positives/ True positives + False negatives) % for 
male FM, female FM, male PM, female PM, Female normal mosaics, female FM 
mosaics, male normal mosaics, male FM mosaics.  





CE + 211 
artifact 
Sensitivity by 
CE + 211 
artifact + UV 
Male FM 43 0 88.37% 90.70 % 
Female FM 23 0 73.91% 73.91% 
Male PM 65 100% 100% NA 








1 0 100% 100% 
Male Mosaic 
Normal 
1 100% 100% 100% 
Male Mosaic 
Full 





Table 16. Specificity (True negatives/ True negative + False Positives) % 
for male FM, female FM, male PM, female PM, Female normal mosaics, female 









CE + 211 
artifact 
Specificity by CE + 
211 artifact + UV 
Male Full Muts 43 100% 100% 100% 
Female Full Muts 23 100% 100% 100% 
Male Pre muts 65 100% 98.46% 98.46% 
Female Pre 86 100% 100% 100% 
Female Mosaic 
  
1 100% 100% 100% 
Female Mosaic 
  
1 100% 100% 100% 
Male Mosaic 
 
1 100% 100% 100% 
Male Mosaic Full 2 100% 100% 100% 
 
One premutation sample showed the 211 artifact bringing the specificity to 
98.46%. This could be due to a small population of full mutation cells not 
detected by the Southern blot.   
 
Largest Trinucleotide Repeats Detected  
The largest PCR product detected by CE alone was a male PM with 147 
repeats. It was detected at 139 by the electropherogram; the 8 repeat difference 
from the label could mean that this sample was originally run on the ARUP home 
brew assay that was in use previous to the Celera assay. The largest product 
detected by CE + 211 artifact was a male FM 1000. A summary of the largest 
product detected for large FM alleles and high PM/low repeat FM alleles is in 
Table 17. Figure 8 is the electropherogram of the largest capillary product 
detected and Figure 9 shows the largest UV Product seen.  
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Table 17. Largest repeats detected by CE, CE+ 211, CE + 211+ UV gel. 
Genotype  CE CE + 211 artifact CE + 211 artifact 
+ UV gel 
Full Mutation males  N/A 1000 1000 
Full Mutation Female N/A 950 950 
Pre-mut/ low FM male 147 N/A 200 
























Figure 9.  UV agarose signal of largest product detected by UV. 
 
 
DNA Quality Evaluation and Second DNA Sample Set 
To evaluate whether the poor quality of the archived DNA was affecting 
the PCR amplification and detection of the full mutation regions, a second set of 
DNA from a smaller, more recently extracted set of 17 deidentified full mutation 
patients was amplified. One was degraded and 4 were mislabeled. The labeled 
genotypes and detected genotypes are in Table 18.  All 12 of the nonarchived 
samples showed the 211 artifact and had better results on the UV gels as well. 
Table 19 shows the number of samples detected by CE, CE with UV and CE by 




Marker  ↑ Smear  
From DNA 
Degradation 
  ←Full Mutation Band 
Female PM → 
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Table 18. Mislabeled samples from recently extracted DNA set.  
Sample # Label genotype Genotype detected 
273 F500/30 M full mutation 
274 M600 F30/full mutation  
276 F600/35 M full mutation 




Table 19. Sensitivity for second set on nonarchived FM DNA.  





CE + 211 
artifact 
Sensitivity by 
CE + 211 
artifact + gel 
Female Full Muts 3 0 3 (100%) 3 (100%) 



















With the prevalence of FxS and the recent discoveries about the 
pathogenesis and prevalence of the premutation disorders the molecular 
detection paradigm of this disease becomes increasingly relevant. The high 
sensitivity and specificity of this assay suggests that it could be an effective tool 
not only for FxS, FXTAS and POI diagnosis but for carrier or newborn screening. 
Screening for FMR1 status has multiple applications: testing of pregnant females 
for potential fetal genotype, informing prepregnancy family planning or for 
premutation related disorder potential. However, there are ethical, legal and 
social concerns that are emerging due to the complexity, unpredictability and 
variability of FMR1 inheritance and the broad expression of phenotype for all 
three FMR1 disorders. The American College of Medical Genetics (ACMG) has 
not recommended FMR1 for screening because of a lack of a cost effective test, 
the absence of data that there are benefits from screening and the possibility of 
negative effects.57 The potential negative effects are myriad, and impact not only 
the mother and child, but other family members on social and medical levels. 
Identifying premutation carriers or full mutation patients gives implied genotype 
status for other family members without their consent or appropriate education on 
the genetic issues related to FMR1. There are studies that support the idea that 
early supportive therapy can be a benefit for FxS patients and families but there 
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are no data suggesting that this is true for FXTAS or POI. 10 The broad variability 
in expression could result in patients with mild, high functioning phenotypes 
being harmed by a diagnosis. Other genetic abnormalities, such as Klinefelter 
and Turner syndrome, could be detected with this assay as well.57  To determine 
the accurate risk for pregnant carriers with premutation alleles passing a full 
mutation form of the allele they would need additional haplotype analysis and 
determination of the status of the stabilizing AGG elements in the CGG repeat. 
There are no commercially available tests for this information currently.  With 
these complications, it is unlikely that there will be resolution on the 
appropriateness of prenatal or new born screening by the ACMG or other 
relevant parties soon.58  
The purpose of this experiment was to evaluate the ability of the Celera kit 
to detect full mutation, premutation and mosaic samples both male and female 
using a combination of the regular CE protocol, a long injection protocol and the 
homemade 1.5% gels with the idea that Southern blotting could be eliminated 
from the current molecular diagnostic procedure.  
The major findings were that no full mutation alleles were seen by CE with 
fluorescent detection without considering the FM fluorescent artifact. The 
detection rate for those full mutation samples by CE without the 211 artifact with 
UV detection was 0% for female full mutation samples and 44% for male full 
mutations. The detection rate using the CE + 211 + UV detection for male FM 
alleles was 90.70% and for female FM alleles was 73.9%. This could be used as 
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a qualitative indicator that the sample should be reflexed to Southern blotting, but 
is not informative for actual repeat region size.  
This supports the hypothesis that Southern blotting could be eliminated for 
normal males, low premutation samples and normal female heterozygotes. 
Female homozygotes, male and females with large premutation alleles or full 
mutations or possible mosaic samples should still be reflexed to Southern 
blotting after evaluation of the electropherograms for a 211 artifact, and the UV 
gel for the presence or absence of a larger allele. This could decrease the 
processing time and expense for the majority of patients without increasing the 
risk of not detecting full mutation alleles. 
The long injection protocol did not enable detection of larger premutation 
signals or any full mutations. The 211 artifact did not show up in any of the long 
injections.  The longer injection was useful to boost amplitude on some samples 
with very poor amplification and normal to low premutation genotypes.  
These findings are in concordance with the claims of Celera, Abbott 
Molecular and their collaborators from Oregon Health and Science University in 
the poster session at the 2006 ACMG meeting.59  They have published that the 
largest repeat detected is 230 repeats and this study has the largest CE allele at 
147. It is possible that there is some confusion that the capillary 211 artifact is 
actual signal. At the 2009 AMP meeting, Asuragen had a poster that showed the 
same 211 artifact. They call it a compression product and state that its presence 
is diagnostic for a full mutation. 60 
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The experiment could be improved with better quality agarose gels. The 
Celera recipe made a gel that was very fragile and gave a less intense UV signal 
than gels available commercially.  It is not clear that the 1.5% agarose 
concentration or the combination of Nusieve and Seakem agarose type is 
essential for detection and sizing of large alleles.  It is also possible that changing 
the polymer type and the injection protocols could mitigate the conditions that 
caused the compression and/or lack of migration of the full mutation PCR product 
and boost detection rate for larger repeat alleles.  More research into the 
repeatability of the 211 artifact with higher quality genomic DNA needs to be 
done to reflect the conditions that would be relevant in the clinical lab.  
In summary this study demonstrated that the Celera and Abbott Molecular 
kit, combined with use of the 211 capillary artifact, and agarose gels with reflex to 
Southern blotting for female apparent homozygotes, patients with large 
premutation repeat regions and possible mosaics is an effective testing method 
with low risk of nondetection of patients with full mutations or mosaicism. The 
long injection protocol does not enable detection of full mutation or large 
premutation alleles, but can be useful for resolving samples with poor 
amplification.  
With these findings it is perhaps time to reassess the ACMG’s current 
recommendations about Fragile X screening. There are three screening 
applications that are being considered by the genetic community; carrier testing 
in pregnant or prepregnant females, newborn screening in males and females, 
newborn screening for methylated alleles. This assay gives no information about 
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methylation status but could be used effectively for the carrier testing or the 
newborn screening. With the specificity being almost 100% for all genotypes and 
the sensitivity for male full mutations being 90% it would be useful for screening 
newborn males. The sensitivity for females was 73% for full mutations and 98% 
for premutation carriers. This makes it less useful for screening full mutation 
female newborns, but an excellent method to detect pregnant or prepregnant 
carriers. With the complexity of the FMR1 related transmission and phenotypes, 
the screening algorithm needs much consideration and discussion, but that 
conversation can be enabled by the improved detection methods discussed in 
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